{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:22:44Z","timestamp":1787656964759,"version":"build-2736575974"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j intensive care"],"DOI":"10.1186\/s40560-026-00932-0","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:26:02Z","timestamp":1787649962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Timing of hemoadsorption in sepsis: redefining early through mediator-guided therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Prit","family":"Kusirisin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kellum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8544-8132","authenticated-orcid":false,"given":"Nattachai","family":"Srisawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"22","key":"932_CR1","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1056\/NEJMra2403213","volume":"391","author":"NJ Meyer","year":"2024","unstructured":"Meyer NJ, Prescott HC. Sepsis and septic shock. N Engl J Med. 2024;391(22):2133\u201346.","journal-title":"N Engl J Med"},{"issue":"10219","key":"932_CR2","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","volume":"395","author":"KE Rudd","year":"1990","unstructured":"Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 1990;395(10219):200\u201311.","journal-title":"Lancet"},{"issue":"8","key":"932_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310.","journal-title":"JAMA"},{"key":"932_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40635-026-00911-7","author":"S David","year":"2026","unstructured":"David S, Leone M, Girardis M, Muller MM, Gavrilovic S, Domizi R, et al. Innovation in sepsis trials: rethinking endpoints, statistics and patient stratification. Intensive Care Med Exp. 2026. https:\/\/doi.org\/10.1186\/s40635-026-00911-7.","journal-title":"Intensive Care Med Exp"},{"issue":"Suppl 3","key":"932_CR5","first-page":"1","volume":"47","author":"C Monard","year":"2019","unstructured":"Monard C, Rimmele T, Ronco C. Extracorporeal blood purification therapies for sepsis. Blood Purif. 2019;47(Suppl 3):1\u201314.","journal-title":"Blood Purif"},{"issue":"6","key":"932_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41581-023-00683-3","volume":"19","author":"A Zarbock","year":"2023","unstructured":"Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19(6):401\u201317.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"932_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00134-026-08361-1","volume":"52","author":"HC Prescott","year":"2026","unstructured":"Prescott HC, Antonelli M, Alhazzani W, Moller MH, Alshamsi F, Azevedo LCP, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Intensive Care Med. 2026;52(5):863\u2013936.","journal-title":"Intensive Care Med"},{"key":"932_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020379","author":"L Mazgaeen","year":"2020","unstructured":"Mazgaeen L, Gurung P. Recent advances in lipopolysaccharide recognition systems. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21020379.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"932_CR9","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840\u201351.","journal-title":"N Engl J Med"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"932_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjsurg.2003.12.067","volume":"188","author":"S Ono","year":"2004","unstructured":"Ono S, Tsujimoto H, Matsumoto A, Ikuta S, Kinoshita M, Mochizuki H. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber. Am J Surg. 2004;188(2):150\u20136.","journal-title":"Am J Surg"},{"issue":"1","key":"932_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-022-04009-w","volume":"26","author":"C Ronco","year":"2022","unstructured":"Ronco C, Bellomo R. Hemoperfusion: technical aspects and state of the art. Crit Care. 2022;26(1):135.","journal-title":"Crit Care"},{"issue":"1","key":"932_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13613-019-0530-y","volume":"9","author":"PM Honore","year":"2019","unstructured":"Honore PM, Hoste E, Molnar Z, Jacobs R, Joannes-Boyau O, Malbrain M, et al. Cytokine removal in human septic shock: where are we and where are we going? Ann Intensive Care. 2019;9(1):56.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"932_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/cc9411","volume":"15","author":"T Rimmele","year":"2011","unstructured":"Rimmele T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205.","journal-title":"Crit Care"},{"issue":"1","key":"932_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000074937","volume":"22","author":"C Ronco","year":"2004","unstructured":"Ronco C, Bonello M, Bordoni V, Ricci Z, D\u2019Intini V, Bellomo R, et al. Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis. Blood Purif. 2004;22(1):164\u201374.","journal-title":"Blood Purif"},{"issue":"3","key":"932_CR16","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/01.CCM.0000115262.31804.46","volume":"32","author":"PM Honore","year":"2004","unstructured":"Honore PM, Matson JR. Extracorporeal removal for sepsis: acting at the tissue level--the beginning of a new era for this treatment modality in septic shock. Crit Care Med. 2004;32(3):896\u20137.","journal-title":"Crit Care Med"},{"issue":"8","key":"932_CR17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/039139880502800803","volume":"28","author":"JV Di Carlo","year":"2005","unstructured":"Di Carlo JV, Alexander SR. Hemofiltration for cytokine-driven illnesses: the mediator delivery hypothesis. Int J Artif Organs. 2005;28(8):777\u201386.","journal-title":"Int J Artif Organs"},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1159\/000313773","volume":"165","author":"Z Peng","year":"2010","unstructured":"Peng Z, Singbartl K, Simon P, Rimmele T, Bishop J, Clermont G, et al. Blood purification in sepsis: a new paradigm. Contrib Nephrol. 2010;165:322\u20138.","journal-title":"Contrib Nephrol"},{"issue":"4","key":"932_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/cc13969","volume":"18","author":"ZY Peng","year":"2014","unstructured":"Peng ZY, Bishop JV, Wen XY, Elder MM, Zhou F, Chuasuwan A, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care. 2014;18(4):R141.","journal-title":"Crit Care"},{"issue":"2","key":"932_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0002-9440(10)64014-X","volume":"158","author":"DR Call","year":"2001","unstructured":"Call DR, Nemzek JA, Ebong SJ, Bolgos GL, Newcomb DE, Remick DG. Ratio of local to systemic chemokine concentrations regulates neutrophil recruitment. Am J Pathol. 2001;158(2):715\u201321.","journal-title":"Am J Pathol"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/978-3-031-11570-7_21","volume-title":"Innovations in nephrology: breakthrough technologies in kidney disease care","author":"P Kusirisin","year":"2022","unstructured":"Kusirisin P, Kaewdoungtien P, Thanapongsatorn P, Peerapornratana S, Srisawat N. Innovations in intensive care nephrology. In: da Silva Junior GB, Nangaku M, editors. Innovations in nephrology: breakthrough technologies in kidney disease care. Cham: Springer; 2022. p. 343\u201363."},{"issue":"2","key":"932_CR22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s00134-018-5464-6","volume":"45","author":"EC Poli","year":"2019","unstructured":"Poli EC, Rimmele T, Schneider AG. Hemoadsorption with CytoSorb((R)). Intensive Care Med. 2019;45(2):236\u20139.","journal-title":"Intensive Care Med"},{"issue":"5","key":"932_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000047487","volume":"105","author":"Q Du","year":"2026","unstructured":"Du Q. Efficacy of CA330 hemoadsorption combined with CRRT in sepsis-associated acute kidney injury: a retrospective cohort study. Medicine (Baltimore). 2026;105(5):e47487.","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"932_CR24","first-page":"122","volume":"54","author":"Y Li","year":"2025","unstructured":"Li Y, Han M, Yang M, Su B. Hemoperfusion with the HA330\/HA380 cartridge in intensive care settings: a state-of-the-art review. Blood Purif. 2025;54(2):122\u201337.","journal-title":"Blood Purif"},{"issue":"12","key":"932_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.4103\/0972-5229.146305","volume":"18","author":"HP Shum","year":"2014","unstructured":"Shum HP, Leung YW, Lam SM, Chan KC, Yan WW. Alteco endotoxin hemoadsorption in Gram-negative septic shock patients. Indian J Crit Care Med. 2014;18(12):783\u20138.","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"932_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1046\/j.1526-0968.2003.00005.x","volume":"7","author":"H Shoji","year":"2003","unstructured":"Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003;7(1):108\u201314.","journal-title":"Ther Apher Dial"},{"key":"932_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000544989","volume":"55","author":"JA Kellum","year":"2025","unstructured":"Kellum JA, Kamaluddin E, Foster D. Targeted rapid endotoxin adsorption: can we bring precision medicine to sepsis? Blood Purif. 2025;55:1\u201312.","journal-title":"Blood Purif"},{"issue":"6","key":"932_CR28","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1097\/SHK.0000000000002121","volume":"59","author":"S Rey","year":"2023","unstructured":"Rey S, Kulabukhov VM, Popov A, Nikitina O, Berdnikov G, Magomedov M, et al. Hemoperfusion using the Lps-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial. Shock. 2023;59(6):846\u201354.","journal-title":"Shock"},{"key":"932_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/membranes11100767","author":"N Said","year":"2021","unstructured":"Said N, Lau WJ, Ho YC, Lim SK, Zainol Abidin MN, Ismail AF. A review of commercial developments and recent laboratory research of dialyzers and membranes for hemodialysis application. Membranes. 2021. https:\/\/doi.org\/10.3390\/membranes11100767.","journal-title":"Membranes"},{"issue":"1","key":"932_CR30","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1186\/s12879-022-07689-5","volume":"22","author":"Y Li","year":"2022","unstructured":"Li Y, Li H, Guo J, Wang Y, Zhang D. Coupled plasma filtration adsorption for the treatment of sepsis or septic shock: a systematic review and meta-analysis. BMC Infect Dis. 2022;22(1):714.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"932_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13054-022-04044-7","volume":"26","author":"G Eden","year":"2022","unstructured":"Eden G, Schmidt JJ, Buttner S, Kumpers P, Hafer C, Rovas A, et al. Safety and efficacy of the Seraph(R) 100 Microbind(R) Affinity Blood Filter to remove bacteria from the blood stream: results of the first in human study. Crit Care. 2022;26(1):181.","journal-title":"Crit Care"},{"issue":"6","key":"932_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2215\/CJN.0000000000000433","volume":"19","author":"R Bellomo","year":"2024","unstructured":"Bellomo R, Mehta RL, Forni LG, Zarbock A, Ostermann M, Ronco C. Hemoadsorption. Clin J Am Soc Nephrol. 2024;19(6):803\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"932_CR33","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/archinte.167.15.1655","volume":"167","author":"JA Kellum","year":"2007","unstructured":"Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med. 2007;167(15):1655\u201363.","journal-title":"Arch Intern Med"},{"issue":"3","key":"932_CR34","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/CCM.0000000000002206","volume":"45","author":"JA Kellum","year":"2017","unstructured":"Kellum JA, Pike F, Yealy DM, Huang DT, Shapiro NI, Angus DC. Relationship between alternative resuscitation strategies, host response and injury biomarkers, and outcome in septic shock: analysis of the Protocol-Based Care for Early Septic Shock study. Crit Care Med. 2017;45(3):438\u201345.","journal-title":"Crit Care Med"},{"issue":"7","key":"932_CR35","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-2600(26)00040-8","volume":"14","author":"K Reddy","year":"2026","unstructured":"Reddy K, Sinha P, Antcliffe DB, McDowell C, Bradley PA, Black L, et al. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study. Lancet Respir Med. 2026;14(7):589\u2013600.","journal-title":"Lancet Respir Med"},{"issue":"11","key":"932_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S2213-2600(23)00237-0","volume":"11","author":"P Sinha","year":"2023","unstructured":"Sinha P, Kerchberger VE, Willmore A, Chambers J, Zhuo H, Abbott J, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials. Lancet Respir Med. 2023;11(11):965\u201374.","journal-title":"Lancet Respir Med"},{"key":"932_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI197346","author":"R Chanderraj","year":"2026","unstructured":"Chanderraj R, Bartek B, Stringer KA, Tiba MH, Sjoding MW, He Y, et al. Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis. J Clin Invest. 2026. https:\/\/doi.org\/10.1172\/JCI197346.","journal-title":"J Clin Invest"},{"issue":"20","key":"932_CR38","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317.","journal-title":"JAMA"},{"issue":"1","key":"932_CR39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13054-022-03977-3","volume":"26","author":"Y Qin","year":"2022","unstructured":"Qin Y, Kernan KF, Fan Z, Park HJ, Kim S, Canna SW, et al. Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials. Crit Care. 2022;26(1):128.","journal-title":"Crit Care"},{"issue":"1","key":"932_CR40","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13054-023-04533-3","volume":"27","author":"I Osawa","year":"2023","unstructured":"Osawa I, Goto T, Kudo D, Hayakawa M, Yamakawa K, Kushimoto S, et al. Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care. 2023;27(1):245.","journal-title":"Crit Care"},{"issue":"1","key":"932_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04690-5","volume":"27","author":"JA Kellum","year":"2023","unstructured":"Kellum JA, Ronco C. The role of endotoxin in septic shock. Crit Care. 2023;27(1):400.","journal-title":"Crit Care"},{"issue":"1","key":"932_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04310-2","volume":"27","author":"C Ronco","year":"2023","unstructured":"Ronco C, Chawla L, Husain-Syed F, Kellum JA. Rationale for sequential extracorporeal therapy (SET) in sepsis. Crit Care. 2023;27(1):50.","journal-title":"Crit Care"},{"issue":"2","key":"932_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/SHK.0000000000001503","volume":"54","author":"M Lipcsey","year":"2020","unstructured":"Lipcsey M, Tenhunen J, Pischke SE, Kuitunen A, Flaatten H, De Geer L, et al. Endotoxin removal in septic shock with the Alteco LPS adsorber was safe but showed no benefit compared to placebo in the double-blind randomized controlled trial-the Asset study. Shock. 2020;54(2):224\u201331.","journal-title":"Shock"},{"issue":"23","key":"932_CR44","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1001\/jama.2009.856","volume":"301","author":"DN Cruz","year":"2009","unstructured":"Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445\u201352.","journal-title":"JAMA"},{"issue":"6","key":"932_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975\u201384.","journal-title":"Intensive Care Med"},{"issue":"14","key":"932_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2018.14618","volume":"320","author":"RP Dellinger","year":"2018","unstructured":"Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA. 2018;320(14):1455\u201363.","journal-title":"JAMA"},{"issue":"1","key":"932_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2077-y","volume":"22","author":"N Srisawat","year":"2018","unstructured":"Srisawat N, Tungsanga S, Lumlertgul N, Komaenthammasophon C, Peerapornratana S, Thamrongsat N, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care. 2018;22(1):279.","journal-title":"Crit Care"},{"issue":"8","key":"932_CR48","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1097\/CCM.0000000000002362","volume":"45","author":"T Chang","year":"2017","unstructured":"Chang T, Tu YK, Lee CT, Chao A, Huang CH, Wang MJ, et al. Effects of polymyxin B hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med. 2017;45(8):e858\u201364.","journal-title":"Crit Care Med"},{"issue":"12","key":"932_CR49","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","volume":"44","author":"DJ Klein","year":"2018","unstructured":"Klein DJ, Foster D, Walker PM, Bagshaw SM, Mekonnen H, Antonelli M. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med. 2018;44(12):2205\u201312.","journal-title":"Intensive Care Med"},{"issue":"5","key":"932_CR50","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S2213-2600(26)00047-0","volume":"14","author":"JA Neyra","year":"2026","unstructured":"Neyra JA, Legrand M, Tidswell MA, Al-Khafaji A, Galphin C, Rains R, et al. Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. Lancet Respir Med. 2026;14(5):443\u201352.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"932_CR51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000534914","volume":"53","author":"P Kusirisin","year":"2024","unstructured":"Kusirisin P, Noppakun K, Trongtrakul K, Vongsanim S, Suteeka Y, Ophascharoensuk V, et al. Efficacy of the cytokine adsorption therapy in patients with severe COVID-19-associated pneumonia: lesson learned from a prospective observational study. Blood Purif. 2024;53(1):10\u201322.","journal-title":"Blood Purif"},{"issue":"1","key":"932_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13054-017-1662-9","volume":"21","author":"K Kogelmann","year":"2017","unstructured":"Kogelmann K, Jarczak D, Scheller M, Druner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21(1):74.","journal-title":"Crit Care"},{"issue":"10","key":"932_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187015","volume":"12","author":"D Schadler","year":"2017","unstructured":"Schadler D, Pausch C, Heise D, Meier-Hellmann A, Brederlau J, Weiler N, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS ONE. 2017;12(10):e0187015.","journal-title":"PLoS ONE"},{"key":"932_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jcrc.2018.11.003","volume":"49","author":"F Hawchar","year":"2019","unstructured":"Hawchar F, Laszlo I, Oveges N, Trasy D, Ondrik Z, Molnar Z. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172\u20138.","journal-title":"J Crit Care"},{"issue":"7","key":"932_CR55","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-2600(21)00177-6","volume":"9","author":"A Supady","year":"2021","unstructured":"Supady A, Weber E, Rieder M, Lother A, Niklaus T, Zahn T, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med. 2021;9(7):755\u201362.","journal-title":"Lancet Respir Med"},{"issue":"6","key":"932_CR56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1744-9987.2010.00825.x","volume":"14","author":"Z Huang","year":"2010","unstructured":"Huang Z, Wang SR, Su W, Liu JY. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column. Ther Apher Dial. 2010;14(6):596\u2013602.","journal-title":"Ther Apher Dial"},{"issue":"6","key":"932_CR57","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1159\/000530446","volume":"52","author":"T Siripanadorn","year":"2023","unstructured":"Siripanadorn T, Samransamruajkit R. The role of blood purification by HA330 as adjunctive treatment in children with septic shock. Blood Purif. 2023;52(6):549\u201355.","journal-title":"Blood Purif"},{"key":"932_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13071113","author":"F Sanchez-Moran","year":"2023","unstructured":"Sanchez-Moran F, Mateu-Campos ML, Bernal-Julian F, Gil-Santana A, Sanchez-Herrero A, Martinez-Gaspar T. Haemoadsorption combined with continuous renal replacement therapy in abdominal sepsis: case report series. J Pers Med. 2023. https:\/\/doi.org\/10.3390\/jpm13071113.","journal-title":"J Pers Med"},{"issue":"4","key":"932_CR59","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1159\/000505565","volume":"49","author":"CK Kacar","year":"2020","unstructured":"Kacar CK, Uzundere O, Kandemir D, Yektas A. Efficacy of HA330 hemoperfusion adsorbent in patients followed in the intensive care unit for septic shock and acute kidney injury and treated with continuous venovenous hemodiafiltration as renal replacement therapy. Blood Purif. 2020;49(4):448\u201356.","journal-title":"Blood Purif"},{"issue":"3","key":"932_CR60","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/1744-9987.14108","volume":"28","author":"J Zhou","year":"2024","unstructured":"Zhou J, Li H, Zhang L, Chen G, Wang G, Zhu H, et al. Removal of inflammatory factors and prognosis of patients with septic shock complicated with acute kidney injury by hemodiafiltration combined with HA330-II hemoperfusion. Ther Apher Dial. 2024;28(3):460\u20136.","journal-title":"Ther Apher Dial"},{"issue":"1","key":"932_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.55730\/1300-0144.5773","volume":"54","author":"S Efe","year":"2024","unstructured":"Efe S, Hanci P, Inal V. Survival benefit of resin cartridge extracorporeal blood purification therapy in patients with septic shock. Turk J Med Sci. 2024;54(1):128\u201335.","journal-title":"Turk J Med Sci"},{"issue":"21","key":"932_CR62","first-page":"8112","volume":"26","author":"MA Erkurt","year":"2022","unstructured":"Erkurt MA, Sarici A, Ozer AB, Kuku I, Bicim S, Aydogan MS, et al. The effect of HA330 hemoperfusion adsorbent method on inflammatory markers and end-organ damage levels in sepsis: a retrospective single center study. Eur Rev Med Pharmacol Sci. 2022;26(21):8112\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"932_CR63","doi-asserted-by":"crossref","unstructured":"Wongtirawit N, Inyu W, Prajantasen U, Phairatwet P, Ratanarat R. HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE). Crit Care. 2026.","DOI":"10.1186\/s13054-026-06121-7"},{"issue":"5","key":"932_CR64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/cc1528","volume":"6","author":"JA Kellum","year":"2002","unstructured":"Kellum JA, Dishart MK. Effect of hemofiltration filter adsorption on circulating IL-6 levels in septic rats. Crit Care. 2002;6(5):429\u201333.","journal-title":"Crit Care"},{"issue":"Suppl 3","key":"932_CR65","first-page":"1","volume":"47","author":"F Turani","year":"2019","unstructured":"Turani F, Barchetta R, Falco M, Busatti S, Weltert L. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif. 2019;47(Suppl 3):1\u20135.","journal-title":"Blood Purif"},{"issue":"8","key":"932_CR66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220444","volume":"14","author":"ME Broman","year":"2019","unstructured":"Broman ME, Hansson F, Vincent JL, Bodelsson M. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE. 2019;14(8):e0220444.","journal-title":"PLoS ONE"},{"issue":"Suppl 3","key":"932_CR67","first-page":"1","volume":"47","author":"L Zhang","year":"2019","unstructured":"Zhang L, Yan Tang GK, Liu S, Cai J, Chan WM, Yang Y, et al. Hemofilter with adsorptive capacities: case report series. Blood Purif. 2019;47(Suppl 3):1\u20136.","journal-title":"Blood Purif"},{"issue":"1","key":"932_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/0391398820917150","volume":"44","author":"N Lumlertgul","year":"2021","unstructured":"Lumlertgul N, Srisawat N. The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: a single-centre experience. Int J Artif Organs. 2021;44(1):17\u201324.","journal-title":"Int J Artif Organs"},{"issue":"Suppl 3","key":"932_CR69","first-page":"1","volume":"47","author":"V Schwindenhammer","year":"2019","unstructured":"Schwindenhammer V, Girardot T, Chaulier K, Gregoire A, Monard C, Huriaux L, et al. oXiris(R) use in septic shock: experience of two French centres. Blood Purif. 2019;47(Suppl 3):1\u20137.","journal-title":"Blood Purif"},{"issue":"1","key":"932_CR70","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13613-023-01224-8","volume":"13","author":"PD Wendel-Garcia","year":"2023","unstructured":"Wendel-Garcia PD, Eberle B, Kleinert EM, Hilty MP, Blumenthal S, Spanaus K, et al. Effects of enhanced adsorption haemofiltration versus haemoadsorption in severe, refractory septic shock with high levels of endotoxemia: the ENDoX bicentric, randomized, controlled trial. Ann Intensive Care. 2023;13(1):127.","journal-title":"Ann Intensive Care"},{"issue":"Suppl 3","key":"932_CR71","first-page":"1","volume":"47","author":"P Pickkers","year":"2019","unstructured":"Pickkers P, Vassiliou T, Liguts V, Prato F, Tissieres P, Kloesel S, et al. Sepsis management with a blood purification membrane: European experience. Blood Purif. 2019;47(Suppl 3):1\u20139.","journal-title":"Blood Purif"},{"issue":"11","key":"932_CR72","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000548214","volume":"54","author":"L Zhang","year":"2024","unstructured":"Zhang L, Srisawat N, Lee CC, Lee DH, Lee K, Liu Z, et al. Extracorporeal blood purification with the oXiris(R) filter for patients with sepsis and hyperinflammatory conditions: the Asia-Pacific oXiris expert meeting 2024 consensus statements. Blood Purif. 2024;54(11):621\u201338.","journal-title":"Blood Purif"},{"issue":"1","key":"932_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003536","volume":"4","author":"S Livigni","year":"2014","unstructured":"Livigni S, Bertolini G, Rossi C, Ferrari F, Giardino M, Pozzato M, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014;4(1):e003536.","journal-title":"BMJ Open"},{"issue":"12","key":"932_CR74","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-030139","volume":"9","author":"C Gimenez-Esparza","year":"2019","unstructured":"Gimenez-Esparza C, Portillo-Requena C, Colomina-Climent F, Allegue-Gallego JM, Galindo-Martinez M, Molla-Jimenez C, et al. The premature closure of ROMPA clinical trial: mortality reduction in septic shock by plasma adsorption. BMJ Open. 2019;9(12):e030139.","journal-title":"BMJ Open"},{"issue":"11","key":"932_CR75","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00134-021-06501-3","volume":"47","author":"E Garbero","year":"2021","unstructured":"Garbero E, Livigni S, Ferrari F, Finazzi S, Langer M, Malacarne P, et al. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. 2021;47(11):1303\u201311.","journal-title":"Intensive Care Med"},{"key":"932_CR76","doi-asserted-by":"crossref","unstructured":"Molnar Z, Toth T, Ronco C, Teboul JL, Premuzic V, Mitzner S, et al. The role of hemoadsorption in septic shock: toward a personalized approach. Crit Care. 2026.","DOI":"10.1186\/s13054-026-06135-1"},{"issue":"12","key":"932_CR77","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1093\/ndt\/gfae089","volume":"39","author":"R Bellomo","year":"2024","unstructured":"Bellomo R, Ankawi G, Bagshaw SM, Baldwin I, Basu R, Bottari G, et al. Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup. Nephrol Dial Transplant. 2024;39(12):1945\u201364.","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40560-026-00932-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40560-026-00932-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:02:37Z","timestamp":1787655757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40560-026-00932-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1186\/s40560-026-00932-0","relation":{},"ISSN":["2052-0492"],"issn-type":[{"value":"2052-0492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"assertion":[{"value":"17 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAK discloses the following: Employment\/stock: Spectral Medical; Consultancy: AstraZeneca, Baxter, Bayer, BioPorto, Chugai Pharma, Mitsubishi Tanabe; Licensed patents held by the University of Pittsburgh: Cytosorbents, J3RM. NS has received research funding from the US National Institutes of Health (P01AI168148 and R01AI183353 for leptospirosis research) and Jafron (DPMAS project). The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"79"}}